Shattuck Labs reports Q4 net income $7.8M, cash $268.8M; presents initial clinical data for SL-172154 and SL-279252

Shattuck Labs, Inc.

Q4 2021 net income $7.8M ($0.18 diluted) vs net loss $12.0M in Q4 2020; full year net loss $45.0M vs $36.6M.
Revenue $30.1M in Q4 (up from $1.3M) due to Takeda collaboration revenue recognition; R&D expenses $16.2M.
Cash $268.8M as of Dec 31, 2021, sufficient into second half 2024.
Initial clinical data for SL-172154 in ovarian cancer showed favorable safety, target occupancy, and CD40 activation; combination trial planned.
SL-279252 showed anti-tumor activity including partial response in ocular melanoma; dose escalation continues to 24 mg/kg.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.